# US 2025/0145703 A1 · Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145703 A1
- Document ID: US20250145703A1
- Status: Published application
- Kind: A1
- Application number: 18/823,585
- Filed: 2024-09-03
- Published: 2025-05-08
- Earliest claimed: 2013-02-08
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Franco E. DI PADOVA; Thomas HUBER; Jean-Michel RONDEAU
- Web page: https://patentgrep.com/patent/US20250145703A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 2039/505: {comprising antibodies}
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

## Claims

### Claim 1

A method of treating neuroinflammatory disease in a subject in need thereof comprising, administering to said subject an effective amount of an IL-17A binding antibody or antigen-binding portion thereof, wherein said IL-17A binding antibody or antigen-binding portion thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL);
a. wherein said VH comprises the three Complementarity Determining Regions (CDRs) of the amino acid sequence set forth as SEQ ID NO: 12 and wherein said VL comprises the three CDRs of the amino acid sequence set forth as SEQ ID NO:43;
b. wherein said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:3 and wherein said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:42, SEQ ID NO:23, SEQ ID NO: 11; or
c. c. wherein said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and wherein said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:41, SEQ ID NO:5, SEQ ID NO:6, and wherein said antibody inhibits proinflammatory cytokine release from astrocytes.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the neuroinflammatory disease is selected from the group consisting of psychiatric, neurological and neurodegenerative disorders.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said proinflammatory cytokine is selected from the group consisting of IL-6, CXCL1, IL-8, GM-CSF, and CCL2.
a. A method for inhibiting angiogenesis in a subject in need thereof comprising, administering to said subject an effective amount of an IL-17A binding antibody or antigen-binding portion thereof, wherein said L-17A binding antibody or antigen-binding portion thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL);
a. wherein said VH comprises the three Complementarity Determining Regions (CDRs) of the amino acid sequence set forth as SEQ ID NO:12 and wherein said VL comprises the three CDRs of the amino acid sequence set forth as SEQ ID NO:43;
b. wherein said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:3 and wherein said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:42, SEQ ID NO:23, SEQ ID NO:11; or
c. wherein said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and wherein said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:41, SEQ ID NO:5, SEQ ID NO:6, and wherein said antibody inhibits angiogenesis.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antibody or antigen-binding portion thereof is a human antibody or antigen-binding portion thereof, a monoclonal antibody or antigen-binding portion thereof, a chimeric antibody or antigen-binding portion thereof, a humanized antibody or antigen-binding portion thereof, a F(ab′)2 fragment, a dAb fragment, a Fab fragment, or a Fv fragment.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the antibody or antigen-binding portion thereof is a monoclonal antibody, a chimeric antibody, or a humanized antibody.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the antibody or antigen-binding portion thereof is a human antibody.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the human antibody comprises a heavy chain and a light chain, wherein said heavy chain comprises the amino acid sequence set forth as SEQ ID NO:14 and wherein said light chain comprises the amino acid sequence set forth as SEQ ID NO:44.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the antibody or antigen-binding portion thereof is a human antibody or antigen-binding portion thereof, a monoclonal antibody or antigen-binding portion thereof, a chimeric antibody or antigen-binding portion thereof, a humanized antibody or antigen-binding portion thereof, a F(ab′)2 fragment, a dAb fragment, a Fab fragment, or a Fv fragment.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the antibody or antigen-binding portion thereof is a monoclonal antibody, a chimeric antibody, or a humanized antibody.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the antibody or antigen-binding portion thereof is a human antibody.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the human antibody comprises a heavy chain and a light chain, wherein said heavy chain comprises the amino acid sequence set forth as SEQ ID NO: 14 and wherein said light chain comprises the amino acid sequence set forth as SEQ ID NO:44.
